Codexis, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CDXS research report →
Range $5 – $5
Price Chart
About the company
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening.
- CEO
- Alison Moore
- IPO
- 2010
- Employees
- 146
- HQ
- Redwood City, CA, US
Get TickerSpark's AI analysis on CDXS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $110.69M
- P/E
- -5.16
- Fwd P/E
- 9.62
- PEG
- -0.03
- P/S
- 1.25
- P/B
- 2.11
- EV/EBITDA
- -15.25
- Div Yield
- 0.00%
- Gross Margin
- 83.93%
- Op Margin
- -14.42%
- Net Margin
- -21.77%
- ROE
- -43.24%
- ROIC
- -10.21%
Latest fiscal year · YoY change
- Revenue
- $70.39M+18.6%
- Gross Profit
- $61.05M+41.8%
- Op Income
- $-38,332,000
- Net Income
- $-43,974,000+32.6%
- EPS
- $-0.50+43.8%
- OCF Growth
- +60.8%
- FCF Growth
- +55.6%
- 52W High
- $2.98
- 52W Low
- $0.90
- 50D MA
- $1.25
- 200D MA
- $1.78
- Beta
- 2.39
- RSI (14)
- 41
- Avg Volume
- 918.15K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Codexis delivered a fourth straight on-target quarter, raised liquidity, and highlighted growing traction for its ECO Synthesis platform in siRNA manufacturing.· November 12, 2026
- Q3 2026 revenue was $19.3 million, up from $8.6 million a year ago, marking a fourth consecutive quarter of on-target execution.
- Product gross margin improved to 74.5%, and management said full-year 2026 gross margin should land in the low 70s.
- The company raised $25 million net from an equity offering and later entered a $60 million term loan, with $42.5 million drawn to repay existing debt.
- ECO Synthesis scaled to 100 grams with high quality and cycle times were reduced by 40%; management is targeting 500-gram production and then kilo scale.
- Customer interest appears to be shifting from feasibility to deployment, with new engagements involving an siRNA pioneer, a large biopharma company, and CDMOs.
Total revenues were $19.3 million in Q3 2026 versus $8.6 million in Q3 2025. Product gross margin was 74.5% in Q3 2026, and management said that based on the first nine months of 2026 it now expects full-year gross margins in the low 70s. R&D expense was $12.6 million versus $13.9 million a year ago, SG&A was $10.1 million versus $11.2 million, and net loss was $8.1 million versus $19.6 million. Cash, cash equivalents and short-term investments ended Q3 at $72.7 million. For 2026, Codexis reiterated revenue guidance of $72 million to $76 million. Subsequent to quarter-end, the company entered a $60 million senior secured term loan and drew $42.5 million to repay $42 million of existing debt; management said current cash should fund planned operations and capex through 2028.
Alison Moore said Codexis is focused on industrializing ECO Synthesis as an alternative manufacturing platform for oligonucleotide medicines, especially siRNA. Her tone was upbeat and confident, emphasizing progress from proof of concept toward customer deployment, regulatory engagement, and process economics. She said the company is adding capabilities customers need, including stereochemical control, starter-oligo-free synthesis, and tissue-targeting chemistry, while moving toward 500-gram scale and construction of a GMP facility.
Georgia Erbez emphasized the company’s improved operating profile and balance sheet. She highlighted Q3 revenue of $19.3 million, product gross margin of 74.5%, lower R&D of $12.6 million, lower SG&A of $10.1 million, and a reduced net loss of $8.1 million. She also cited the $25 million net equity raise, the $60 million term loan with $42.5 million drawn, the repayment of the $42 million prior debt, and said cash of $72.7 million should be sufficient through 2028. She reiterated 2026 revenue guidance of $72 million to $76 million and said gross margins are expected in the low 70s for the full year.
Analysts focused on what the TIDES Europe data changed in customer conversations, how the FDA is viewing ECO Synthesis, and how new evaluation agreements might convert into revenue. Management said the FDA discussion in late September was constructive and covered enzyme and siRNA specifications plus comparability, including how stereochemical control might be compared with stereo-random solid-phase material. On customers, management said the conversation has shifted from curiosity to deployment planning, with strong interest in scale, purity, stereocontrol, and the ability to transfer the platform into pilot-scale manufacturing. They also said it is difficult to predict timing for new signed deals, though the funnel remains active.
The bull case from this call is that Codexis is showing real technical progress and commercial validation at the same time. Management reported 100-gram production with high quality, a 40% reduction in cycle time, and three- to fourfold greater potency in stereocontrolled siRNA versus a stereo-random control, while also adding customer-facing capabilities and new engagements. Financially, revenue growth, improving gross margin, and stronger liquidity support the idea that the platform is becoming more investable and more credible to partners.
The main risks are that commercialization is still early, deal timing is uncertain, and the company is relying on future adoption to fully monetize the platform. Management repeatedly said it is hard to predict when current discussions will turn into signed, larger contracts, and several programs are still at evaluation or pilot-transfer stages. The business also remains dependent on continued execution in scale-up, regulatory alignment, and proving that the technology can move from 100-gram success to 500-gram and kilo-scale manufacturing.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 81.6%
- Shares Outstanding
- 109.60M
- Float Shares
- 89.45M
of shares held by institutions
151 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for CDXS, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Lamar Seeligson SmithHouse · TX21 | Buy | Apr 6, 18 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Aberdeen Group PLC | 10.80M | ▲ 4.03M |
| Blackrock, Inc. | 8.31M | ▲ 1.03M |
| Telemark Asset Management, LLC | 7.85M | ▲ 4.00M |
| Vanguard Group Inc | 4.94M | ▲ 271.73K |
| Millennium Management LLC | 4.77M | ▼ 779.51K |
| Vanguard Capital Management LLC | 4.34M | ▲ 727.12K |
| Ameriprise Financial Inc | 3.06M | ▼ 754.17K |
| Nantahala Capital Management, LLC | 2.60M | ▼ 1.03M |
| Opaleye Management Inc. | 2.59M | ▼ 4.20M |
| Geode Capital Management, LLC | 2.47M | ▲ 310.24K |
| D. E. Shaw & Co., Inc. | 1.79M | ▲ 444.01K |
| State Street Corp | 1.64M | ▼ 121.43K |
Held by 136 ETFs
Biggest fund positions in CDXS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | MOORE ALISON | sell | 10,651 |
| Nov 9, 26 | De Vre Raymond | sell | 1,088 |
| Oct 12, 26 | Erbez Georgia | sell | 6,335 |
| Oct 12, 26 | MOORE ALISON | sell | 6,335 |
| Jun 17, 26 | PARKER H STEWART | other | 66,350 |
| Jun 17, 26 | Collins Cynthia | other | 66,350 |
| Jun 17, 26 | Richards Christos | other | 66,350 |
| Jun 17, 26 | Smith David V | other | 66,350 |
| Jun 17, 26 | Singhvi Rahul | other | 66,350 |
| Jun 17, 26 | Martinborough Esther | other | 66,350 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CDXS coverage
Recent articles, reports, and earnings notes.
No research on CDXS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CDXS report →Codexis to Participate in Piper Sandler 38th Annual Healthcare Conference
globenewswire.com · Nov 19
Codexis, Inc. (CDXS) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 12
What Codexis (CDXS) Said on Its Q3 Earnings Call
marketbeat.com · Nov 12
Codexis (CDXS) Reports Q3 Loss, Beats Revenue Estimates
zacks.com · Nov 12
Codexis Reports Third Quarter 2026 Financial Results and Provides Business Update
globenewswire.com · Nov 12
Comparing Codexis (NASDAQ:CDXS) and Bionano Genomics (NASDAQ:BNGO)
defenseworld.net · Nov 11
Codexis Enters into $60 Million Term Loan Facility with Trinity Capital
globenewswire.com · Nov 10
Codexis Advances ECO Synthesis Toward Adoption Readiness with Quality at Scale and Expanded siRNA Manufacturing Capabilities
globenewswire.com · Nov 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.